Skip to Content

Certriad Approval Status

Certriad (rosuvastatin calcium and fenofibric acid) is a combination of the active ingredients in Crestor and Trilipix intended for the treatment of mixed dyslipidemia.

In March 2010, AstraZeneca and Abbott announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Certriad (rosuvastatin/fenofibric acid delayed release) capsules had not been approved.

Development Status and FDA Approval Process for Certriad

Dec 22, 2010Abbott and AstraZeneca End License Agreement for the Development of Certriad
Mar 30, 2010AstraZeneca and Abbott Receive FDA Complete Response Letter on Certriad New Drug Application
Jun  4, 2009Abbott and AstraZeneca Submit New Drug Application to the FDA for Certriad, an Investigational Treatment for Mixed Dyslipidemia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.